rituximab in life-threatening situations but based on limited evidence Prevent damage Minimize both damage due to systemic lupus erythematosus and as consequence of medications, particularly ...

Genentech. Phase III study of Rituxan in lupus nephritis did not meet primary end point [online], (2009). Biomarin. Results of first interim efficacy analysis for Riquent Phase III ASPEN trial ...

The anti-CD20 mechanism could also lead to some competition for GSK in SLE and lupus nephritis. While Roche wasn’t able to show efficacy for its Rituxan brand of rituximab in trials, follow-up ...

“Although B-cell depletion with rituximab has become a widely used therapy for the treatment of rheumatic diseases, such as rheumatoid arthritis and vasculitis, studies in systemic lupus and ...

The positive REGENCY data comes over 15 years after the failure of Roche’s other B-cell depleting therapy, Rituxan (rituximab), in lupus nephritis. Co-developed by Genentech and Biogen ...

severe cases with complications like lupus nephritis could still incur substantial costs, with some estimates reaching around R200,000 per patient per year for treatments like rituximab in the ...

Datamonitor estimates that the lupus drug market in the seven major markets was worth at least US$330 million in 2007. Despite failing its Phase III trial in SLE, rituximab, which we believe ...